




## ADDING IT ALL UP: Funding for HIV Vaccine Development, 2000 to 2005

- In 2005, total global investment (public, philanthropic and commercial sectors together) in preventive HIV vaccine R&D was approximately US\$759 million.
- Between 2000 and 2005, public and the philanthropic investments in HIV vaccines research and development (R&D) more than doubled from US\$327 million to US\$684 million.
- In 2005, the public sector provided about 88% (US\$672 million) of the funds allocated to preventive HIV vaccine R&D, with the philanthropic sector providing 2% (US\$12 million) and the commercial sector accounting for 10% (US\$ 75 million) of funding.
- During the last six years, European funders have increased their commitment to preventive vaccine R&D three fold from US\$23 to US\$69 million. In 2005, R&D continued to grow outside of the US and Europe with contributions from countries such as Brazil, Canada, India, South Africa and Thailand totaling US\$27 million.
- The public sector, particularly in developing countries where trials are planned or are underway, provides considerable non-financial support through staff and facilities. These non-cash contributions are not trivial and have grown considerably over the last six years.
- In 2005, R&D expenditures were predominately on basic and pre-clinical research, which accounted for approximately 64% of the funds spent. In comparison, support for clinical trials accounted for 22%, cohort and site development for 13%, and advocacy and policy development 1%.
- As of July 31 2006, preliminary public sector and philanthropic commitments for 2006 equaled US\$781 million; a 14% combined increase for these two sectors over 2005. This increase may not be sustained in subsequent years, as it reflects significant new investments by the Bill & Melinda Gates Foundation and the US National Institutes of Health.
- Although investment in preventive HIV vaccines increased in 2005, the Global HIV Vaccine Enterprise estimates that between US\$1.1-US\$1.2 billion is needed annually to speed the search for a safe, effective HIV vaccine.

### Public Sector Investment 2000 and 2005



Note: "Other Public Sector" refers to funding from national governments apart from the US and the countries of Europe, and funding from multilateral organizations.


The areas of the pie charts are proportionate to total public sector funding in 2000 and 2005. The increase in the size of the pies reflects the percentage growth in funding over this period.



## ADDING IT ALL UP: Funding for Microbicide Development, 2000 to 2005

- In 2005, total global investment (public, philanthropic and commercial sectors together) in microbicide R&D was approximately US\$ 168 million.
- Between 2000 and 2005, public and the philanthropic investments in microbicides research and development (R&D) more than doubled from US\$65 million to US\$164 million.
- In 2005, public sector funders provided 85% (US\$143 million) of the funds allocated to microbicide R&D, with the philanthropic section providing 13% (US\$21.3 million) and the commercial sector accounting for approximately 2% (US\$4.5 million).
- During the last six years, European funders have increased their commitment to microbicide R&D over forty-fold from US\$0.7 to US\$30 million. In 2005, R&D continued to grow outside of the US and Europe with contributions from countries such as Brazil, Canada, and South Africa totaled US\$ 10.5 million.
- The public sector, particularly in developing countries where trials are planned or are underway, provides considerable non-financial support through staff and facilities. These non-cash contributions are not trivial and have grown considerably over the last six years.
- Expenditures for microbicide R&D in 2005 were predominately on pre-clinical and clinical research, which respectively accounted for 26% and 45% of funds spent. In comparison, basic research accounted for 16%, cohort and site development for 8%, and advocacy and policy development 5%.
- As of July 31, 2006, preliminary public sector and philanthropic commitments for 2006 equaled US\$169 million.
- Although microbicide R&D investment increased in 2005, the Alliance for Microbicide Development and the International Partnership for Microbicides estimates that US\$280 million per year will be required over the next five years to accelerate the search for a safe and effective microbicide.

### Public Sector Investment 2000 and 2005



Note: "Other Public Sector" refers to funding from national governments apart from the US and the countries of Europe, and funding from multilateral organizations.

The areas of the pie charts are proportionate to total public sector funding in 2000 and 2005. The increase in the size of the pies reflects the percentage growth in funding over this period.